Recent Quotes
My Watchlist
Indicators
Local Stocks
NewsOK Local Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Summit Therapeu ADR (NQ: SMMT )

18.92 -0.17 (-0.89%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,133,654
Open 19.25
Bid (Size) 18.90 (1)
Ask (Size) 18.92 (35)
Prev. Close 19.09
Today's Range 18.44 - 19.49
52wk Range 1.640 - 33.89
Shares Outstanding 97,381,774
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
2 Soaring Stocks That Could Climb Another 112% and 120%, According to Wall Street Analysts
The investment bank analysts who follow these stocks think they can soar even further, with some caveats. 
Via The Motley Fool
Coinbase, Nike And Moderna Are Among Top 11 Large Cap Losers Last Week (Sept 30-Oct 4): Are The Others In Your Portfolio?
Eleven large-cap stocks were worst performers last week. Decline in Stars performance and sales, regulations and supply issues caused the drop. 
Via Benzinga

Performance

YTD
+616.67%
+616.67%
1 Month
+54.20%
+54.20%
3 Month
+150.60%
+150.60%
6 Month
+378.99%
+378.99%
1 Year
+1032.93%
+1032.93%

More News

Read More
Is Summit Therapeutics a Millionaire Maker?
Via The Motley Fool
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Summit Therapeutics Inc.
Via Business Wire
Could Summit Therapeutics Become the Next Merck?
Via The Motley Fool
Why Phoenix Motor Shares Are Trading Higher By 150%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Summit Therapeutics Announces Completion of Enrollment in Its Phase III HARMONi Trial in 2L+ EGFRm NSCLC
From Summit Therapeutics Inc.
Via Business Wire
Where Will Summit Therapeutics Be in 3 Years?
Via The Motley Fool
EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In September 2024 – Where Do Tesla, Nvidia, Apple, DJT Stock Rank?
Via Benzinga
Has Summit Therapeutics Stock Already Peaked?
Via The Motley Fool
Is Summit Therapeutics Stock a Buy?
Via The Motley Fool
Regeneron Pharma, Super Micro Computer And Global Payments Are Among Top 10 Large Cap Losers Last Week (Sept 23-Sept 27): Are The Others In Your Portfolio?
Via Benzinga
2 High-Potential Growth Stocks You Shouldn't Overlook
Via The Motley Fool
Better Rising Biotech: Viking Therapeutics vs. Summit Therapeutics
Via The Motley Fool
2 Stocks Up Over 700% in 2024 That Could Soar Even Further
Via The Motley Fool
Novo Nordisk, Chewy And FedEx Are Among Top 10 Large Cap Losers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
Via Benzinga
This Stock Is Crushing Nvidia's Performance This Year: Is It Too Late to Buy?
Via The Motley Fool
Industry Update: 3 Exciting Precision Oncology Players to Watch Following Summit’s Meteoric Rise: Silexion, Nuvectis, Scorpian
Via AB Newswire
Industry Update: 3 Exciting Precision Oncology Players to Watch Following Summit’s Meteoric Rise: Silexion, Nuvectis, Scorpian
Via News Direct
Is It Too Late to Buy Summit Therapeutics Stock After Its Almost 10X Gain This Year?
Via The Motley Fool
This Company Generates No Revenue and Its Market Cap Is Over $20 Billion. Here's Why That Valuation May Not Be All That Ridiculous.
Via The Motley Fool
How BioNTech, Up 25% Over Four Days, Is Riding Summit's Coattails To A Recovery
Via Investor's Business Daily
Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study
Via Benzinga
Here's Why Everyone's Talking About Summit Therapeutics
Via The Motley Fool
Alphabet To $200? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.